Inhibiting Hv1 channel in peripheral sensory neurons attenuates chronic inflammatory pain and opioid side effects
Qiansen Zhang,Yimin Ren,Yiqing Mo,Peipei Guo,Ping Liao,Yuncheng Luo,Jie Mu,Zhuo Chen,Yang Zhang,Ya Li,Linghui Yang,Daqing Liao,Jie Fu,Juwen Shen,Wei Huang,Xuewen Xu,Yanyan Guo,Lianghe Mei,Yunxia Zuo,Jin Liu,Huaiyu Yang,Ruotian Jiang
DOI: https://doi.org/10.1038/s41422-022-00616-y
IF: 44.1
2022-02-03
Cell Research
Abstract:Both opioids and nonsteroidal anti-inflammatory drugs (NSAIDS) produce deleterious side effects and fail to provide sustained relief in patients with chronic inflammatory pain. Peripheral neuroinflammation (PN) is critical for initiation and development of inflammatory pain. A better understanding of molecular mechanisms underlying PN would facilitate the discovery of new analgesic targets and the development of new therapeutics. Emerging evidence suggests that peripheral sensory neurons are not only responders to painful stimuli, but are also actively engaged in inflammation and immunity, whereas the intrinsic regulatory mechanism is poorly understood. Here we report the expression of proton-selective ion channel Hv1 in peripheral sensory neurons in rodents and humans, which was previously shown as selectively expressed in microglia in mammalian central nervous system. Neuronal Hv1 was up-regulated by PN or depolarizing stimulation, which in turn aggravates inflammation and nociception. Inhibiting neuronal Hv1 genetically or by a newly discovered selective inhibitor YHV98-4 reduced intracellular alkalization and ROS production in inflammatory pain, mitigated the imbalance in downstream SHP-1-pAKT signaling, and also diminished pro-inflammatory chemokine release to alleviate nociception and morphine-induced hyperalgesia and tolerance. Thus, our data reveal neuronal Hv1 as a novel target in analgesia strategy and managing opioids-related side effects.
cell biology